Illumina

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Illumina 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ILMN

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. 

CEO
Jacob Thaysen
CEOJacob Thaysen
Employees
10,370
Employees10,370
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
10,370
Employees10,370

ILMN Key Statistics

Market cap
21.62B
Market cap21.62B
Price-Earnings ratio
32.61
Price-Earnings ratio32.61
Dividend yield
Dividend yield
Average volume
1.71M
Average volume1.71M
High today
$148.57
High today$148.57
Low today
$141.35
Low today$141.35
Open price
$146.94
Open price$146.94
Volume
608.62K
Volume608.62K
52 Week high
$153.06
52 Week high$153.06
52 Week low
$68.70
52 Week low$68.70

Stock Snapshot

The current Illumina(ILMN) stock price is $141.47, with a market capitalization of 21.62B. The stock trades at a price-to-earnings (P/E) ratio of 32.61.

During the trading session on 2026-01-14, Illumina(ILMN) shares reached a daily high of $148.57 and a low of $141.35. At a current price of $141.47, the stock is +0.1% higher than the low and still -4.8% under the high.

Trading volume for Illumina(ILMN) stock has reached 608.62K, versus its average volume of 1.71M.

The stock's 52-week range extends from a low of $68.70 to a high of $153.06.

The stock's 52-week range extends from a low of $68.70 to a high of $153.06.

ILMN News

Simply Wall St 56m
Illumina Valuation Check After Recent Share Price Rebound And Conflicting Fair Value Signals

Illumina (ILMN) is back on investors’ screens after recent trading, with the share price closing at US$146.99. The move comes against a backdrop of mixed short...

Illumina Valuation Check After Recent Share Price Rebound And Conflicting Fair Value Signals
TipRanks 7h
Illumina: Rich Valuation Amid Mounting Competitive and Execution Risks Supports Sell Rating

In a report released yesterday, Michael Ryskin from Bank of America Securities maintained a Sell rating on Illumina, with a price target of $80.00. Claim 70% Of...

Nasdaq 1d
Illumina Preliminary Q4, Annual Results Beat Analysts' View

(RTTNews) - Illumina, Inc. (ILMN), a biotechnology company, on Tuesday reported preliminary results for the fourth quarter and fiscal 2025 above analysts' expec...

Illumina Preliminary Q4, Annual Results Beat Analysts' View

Analyst ratings

39%

of 23 ratings
Buy
39.1%
Hold
39.1%
Sell
21.7%

More ILMN News

TipRanks 1d
Illumina introduces Billion Cell Atlas

Illumina (ILMN) introduced the world’s largest genome-wide genetic perturbation dataset, being built to accelerate drug discovery through AI across the pharmace...

Simply Wall St 1d
Is Illumina’s New CMO Hire and Connected Multiomics Cloud Altering The Investment Case For Illumina?

Illumina has recently appointed genomics veteran Eric D. Green, M.D., Ph.D., as Chief Medical Officer and launched its Illumina Connected Multiomics cloud platf...

Is Illumina’s New CMO Hire and Connected Multiomics Cloud Altering The Investment Case For Illumina?
TipRanks 4d
Cathie Wood’s ARK Makes New Biotech Bets in Her Latest Trades — Here’s What It Sold

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several portfolio moves across biotech and industrial names on Friday, January 9, 2026. The firm incr...

TipRanks 6d
Illumina appoints new chief medical officer amid leadership shifts

Claim 70% Off TipRanks Premium An announcement from Illumina ( (ILMN) ) is now available. On January 8, 2026, Illumina announced that veteran genomics leader...

TipRanks 6d
Illumina to name Eric Green chief medical officer, Endpoints News reports

Eric Green, a former NIH director, is expected to become the chief medical officer of Illumina (ILMN), Jared Whitlock of Endpoints News reported. Claim 70% Off...

People also own

Based on the portfolios of people who own ILMN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .